Wedbush restated their outperform rating on shares of Xencor (NASDAQ:XNCR – Free Report) in a research note published on Monday, RTT News reports. Wedbush currently has a $34.00 price objective on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on XNCR. JPMorgan Chase & Co. dropped their price objective on shares of Xencor from $30.00 to $27.00 and set an overweight rating for the company in a report on Wednesday, July 31st. Royal Bank of Canada reaffirmed an outperform rating and issued a $31.00 price objective on shares of Xencor in a research note on Tuesday, August 6th. BMO Capital Markets reissued an outperform rating and set a $32.00 price target on shares of Xencor in a research report on Tuesday, August 6th. Finally, Raymond James dropped their price objective on shares of Xencor from $58.00 to $40.00 and set a strong-buy rating on the stock in a report on Friday, June 14th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $34.44.
Get Our Latest Stock Report on XNCR
Xencor Stock Down 1.5 %
Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative return on equity of 28.23% and a negative net margin of 132.74%. The business had revenue of $16.96 million during the quarter, compared to analyst estimates of $21.13 million. During the same period last year, the company earned ($0.37) EPS. The business’s revenue for the quarter was down 62.7% on a year-over-year basis. On average, analysts anticipate that Xencor will post -4.17 EPS for the current year.
Insider Transactions at Xencor
In other news, VP John R. Desjarlais sold 36,329 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $665,547.28. Following the transaction, the vice president now directly owns 192,319 shares in the company, valued at approximately $3,523,284.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.23% of the stock is owned by company insiders.
Institutional Trading of Xencor
Hedge funds and other institutional investors have recently modified their holdings of the stock. Parallel Advisors LLC boosted its holdings in shares of Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,015 shares during the period. Quarry LP bought a new stake in shares of Xencor during the 2nd quarter worth about $36,000. GAMMA Investing LLC boosted its holdings in shares of Xencor by 153.7% during the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,316 shares during the period. Quest Partners LLC bought a new stake in Xencor in the 4th quarter valued at about $61,000. Finally, Quadrant Capital Group LLC boosted its holdings in Xencor by 475.2% in the 4th quarter. Quadrant Capital Group LLC now owns 4,757 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,930 shares during the period.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
- Five stocks we like better than Xencor
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Leveraged ETFs to Multiply Returns
- What to Know About Investing in Penny Stocks
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- 3 Fintech Stocks With Good 2021 Prospects
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.